Country,Population,Intervention,Guideline Comparators,HTA Comparators,Source Types
AT,Child-Pugh A patients with unresectable HCC,Medicine X (under assessment),"atezolizumab and bevacizumab, best supportive care, durva...","TACE, TACE + sorafenib, placebo, sorafenib","Clinical Guideline, Hta Submission"
BE,patients with unresectable HCC,Medicine X (under assessment),"arterial chemoembolization, hormonal therapy with tamoxif...",-,Clinical Guideline
DE,Child-Pugh A patients with unresectable HCC,Medicine X (under assessment),"TACE, atezolizumab and bevacizumab, best supportive care,...","TACE, TACE + sorafenib, arterial embolization, placebo, s...","Clinical Guideline, Hta Submission"
DK,Adult patients with advanced HCC and adult patients with inoperable HCC.,Medicine X (under assessment),sorafenib,sorafenib,"Clinical Guideline, Hta Submission"
EN,adults with advanced or unresectable HCC with Child-Pugh grade A liver impair...,Medicine X (under assessment),-,"lenvatinib, sorafenib",Hta Submission
ES,adult patients with advanced or unresectable hepatocellular carcinoma who hav...,Medicine X (under assessment),BSC best supportive care,"lenvatinib, placebo, sorafenib","Clinical Guideline, Hta Submission"
FR,patients with advanced or unresectable hepatocellular carcinoma (HCC) (stage ...,Medicine X (under assessment),"atezolizumab plus bevacizumab, best supportive care, cabo...",sorafenib,"Clinical Guideline, Hta Submission"
IT,"patients with advanced HCC, who have failed or are not eligible for local-reg...",Medicine X (under assessment),"FOLFOX4, TACE, doxorubicin, sorafenib",-,Clinical Guideline
NL,patients with advanced hepatocellular carcinoma who had not received previous...,Medicine X (under assessment),"atezolizumab with bevacizumab, lenvatinib, regorafenib, s...","best care regimen available, placebo","Clinical Guideline, Hta Submission"
PO,patients previously treated with Sorafenib with AFP â‰¥ 400 ng/ ml,Medicine X (under assessment),"cabozantinib, combination of bevacizumab and atezolizumab...",-,Clinical Guideline
PT,adult patients with advanced or non-resectable hepatocellular carcinoma (HCC)...,Medicine X (under assessment),-,sorafenib,Hta Submission
SE,patients with HCC with non-viral etiologies,Medicine X (under assessment),"atezolizumab and bevacizumab, cabozantinib, lenvatinib, r...","Lenvima (lenvatinib), Tecentriq (atezolizumab) plus bevac...","Clinical Guideline, Hta Submission"
